Hengrui Pharma (600276) Announces Share Repurchase Update

Bulletin Express

11/04

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma, stock code 600276) filed a Next Day Disclosure Return dated 04 November 2025. The document shows an adjustment in its share capital following a repurchase of 210,000 A shares on 04 November 2025 for the A Share Employee Stock Ownership Schemes. The repurchase occurred on the Shanghai Stock Exchange at prices ranging between RMB 61.6 and RMB 62.3 per share, with a total payment of approximately RMB 13,022,079.8.

After the transaction, the number of issued shares (excluding treasury shares) decreased to 6,362,422,164 from 6,362,632,164, while treasury shares increased to 16,580,110. The total number of shares remained at 6,379,002,274. The filing confirms that all related procedures have been carried out in compliance with applicable listing rules and regulatory requirements.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1164474906"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1164474906\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1164474906?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 16:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164474906","market":"hk","top_or_hot":-1,"title":"Hengrui Pharma (600276) Announces Share Repurchase Update","media":"Bulletin Express","content":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma, stock code 600276) filed a Next Day Disclosure Return dated 04 November 2025. The document shows an adjustment in its share capital following a repurchase of 210,000 A shares on 04 November 2025 for the A Share Employee Stock Ownership Schemes. The repurchase occurred on the Shanghai Stock Exchange at prices ranging between RMB 61.6 and RMB 62.3 per share, with a total payment of approximately RMB 13,022,079.8.</p>\n<p>After the transaction, the number of issued shares (excluding treasury shares) decreased to 6,362,422,164 from 6,362,632,164, while treasury shares increased to 16,580,110. The total number of shares remained at 6,379,002,274. The filing confirms that all related procedures have been carried out in compliance with applicable listing rules and regulatory requirements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hengrui Pharma (600276) Announces Share Repurchase Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHengrui Pharma (600276) Announces Share Repurchase Update\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-11-04 16:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma, stock code 600276) filed a Next Day Disclosure Return dated 04 November 2025. The document shows an adjustment in its share capital following a repurchase of 210,000 A shares on 04 November 2025 for the A Share Employee Stock Ownership Schemes. The repurchase occurred on the Shanghai Stock Exchange at prices ranging between RMB 61.6 and RMB 62.3 per share, with a total payment of approximately RMB 13,022,079.8.</p>\n<p>After the transaction, the number of issued shares (excluding treasury shares) decreased to 6,362,422,164 from 6,362,632,164, while treasury shares increased to 16,580,110. The total number of shares remained at 6,379,002,274. The filing confirms that all related procedures have been carried out in compliance with applicable listing rules and regulatory requirements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01276","symbol_name":"恒瑞医药","start_time":0,"source_url":"","article_id":"1164474906","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164474906","pubTimestamp":1762245901,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma, stock code 600276) filed a Next Day Disclosure Return dated 04 November 2025. The document shows an adjustment in its share capital...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01276":"恒瑞医药"},"translate_title":"恒瑞医药(600276)公布回购股份更新","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01276":1},"content_text":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma, stock code 600276) filed a Next Day Disclosure Return dated 04 November 2025. The document shows an adjustment in its share capital following a repurchase of 210,000 A shares on 04 November 2025 for the A Share Employee Stock Ownership Schemes. The repurchase occurred on the Shanghai Stock Exchange at prices ranging between RMB 61.6 and RMB 62.3 per share, with a total payment of approximately RMB 13,022,079.8.\nAfter the transaction, the number of issued shares (excluding treasury shares) decreased to 6,362,422,164 from 6,362,632,164, while treasury shares increased to 16,580,110. The total number of shares remained at 6,379,002,274. The filing confirms that all related procedures have been carried out in compliance with applicable listing rules and regulatory requirements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}